Status:
COMPLETED
Dexmedetomidine in Erector Spinae Block in Postoperative Analgesia
Lead Sponsor:
Mohamed Elsayed Hassan
Conditions:
Postoperative Pain
Eligibility:
FEMALE
18-70 years
Phase:
NA
Brief Summary
60 female patients scheduled for breast cancer surgeries, allocated in 3 groups for erector spinae block with bupivacaine and erector spinae block with dexmedetomidine added to bupivacaine and control...
Detailed Description
60 female patients scheduled for breast cancer surgeries, allocated in 3 groups for erector spinae block with bupivacaine and erector spinae block with dexmedetomidine added to bupivacaine and control...
Eligibility Criteria
Inclusion
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Female, aged (18-70) years
- Belongs to American Society of Anaesthesiologists physical status class II.
- Scheduled for breast cancer surgeries.
Exclusion
- Patient refusal.
- Local infection at the site of the block.
- Cardiac dysfunction (ejection fraction \<45%).
- Preexisting neurological or psychiatric disease, communication difficulties, inability to use the patient-controlled analgesia (PCA) device.
- Allergy to one of the study drugs.
- Pregnancy.
- Coagulopathy (PC \<60% and platelet count\<100.000).
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT04920669
Start Date
July 1 2021
End Date
September 30 2021
Last Update
April 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Cairo, Egypt